Skip to content
B
BiotechEdge
Start 14-Day Free Trial

Arcellx + Gilead Sciences

pending

$ACLX acquired by Gilead Sciences for $7.8B

Deal Summary

Deal Value
$7.8B
Price/Share
$115
Announced
Feb 18, 2026
Expected Close
TBD

Fund Positioning

4 of 20 tracked specialist biotech funds held $ACLX — based on SEC 13F filings.

FundSharesValueEntryAt Announcement
Perceptive Advisors1.5M$95.6MMar 2025Yes
RA Capital Management1.3M$82.6MMar 2025Yes
Baker Bros. Advisors167K$13.7MJun 2025Yes
Rock Springs Capital170K$11.1MJun 2025Yes
← All biotech acquisitions